Clinical Characterization and Multimodal Management Of Pediatric Acute-Onset Neuropsychiatric Syndrome
IMPACT:
This Insights from the Immunoglobulin National Society academic review article highlights severity-based, multimodal treatment strategies for Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS), the umbrella construct that includes PANDAS, emphasizing integrated psychiatric, infectious, and immune-focused care within a multidisciplinary framework. It also addresses practical considerations for clinicians involved in medication management, including pharmacists, particularly related to treatment sequencing, safety monitoring, off-label immunomodulatory therapies, and access challenges such as intravenous immunoglobulin (IVIG).
SUMMARY
The academic article provides a clinical overview of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS), emphasizing its complex and multifactorial presentation and the need for structured, multidisciplinary evaluation and management. PANS is defined by the abrupt onset of obsessive-compulsive symptoms or severely restricted food intake, accompanied by acute neuropsychiatric changes such as anxiety, emotional lability, irritability, cognitive decline, sensory sensitivities, motor abnormalities, and behavioral regression. The abrupt onset and severity of symptoms are central diagnostic features that distinguish PANS from primary psychiatric conditions.
The authors emphasize that PANS remains a diagnosis of exclusion, with no validated biomarker currently available. Clinicians must carefully rule out alternative neurologic, infectious, metabolic, autoimmune, and primary psychiatric conditions that may present with overlapping symptoms. The proposed pathophysiology is heterogeneous and may include post-infectious immune activation, neuroinflammatory processes, and other systemic triggers. As a result, clinical assessment requires a high degree of diagnostic rigor and a systematic approach to differential diagnosis.
Management is described as multimodal and individualized, targeting three primary domains: psychiatric symptom control, identification and treatment of underlying or concurrent infections when present, and management of suspected immune or inflammatory dysregulation. First-line psychiatric interventions often include cognitive-behavioral therapy and pharmacologic support for obsessive-compulsive symptoms, anxiety, and associated mood or behavioral disturbances. Appropriate antimicrobial therapy may be indicated for infections. In select moderate to severe cases, immunomodulatory therapies may be considered.
A central theme of the article is the importance of coordinated multidisciplinary care involving pediatrics, psychiatry, neurology, immunology, and allied health professionals. This collaborative model supports more accurate diagnosis, safer treatment selection, and ongoing longitudinal monitoring of symptom progression and treatment response.
Overall, the article positions PANS as a clinically significant but still evolving diagnostic entity, requiring both careful exclusion of alternative diagnoses and flexible, patient-centered treatment strategies. It supports a growing clinical consensus that improved outcomes depend on early recognition, integrated care models, and continued investigation into immune–brain interactions.
LINK TO PAPER: http://tinyurl.com/yh3w6prc
CITATION
Pharmacy Practice News. (2026, May). Clinical characterization and multimodal management of pediatric PANS. Immunoglobulin National Society (IgNS) Insights Series.